AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32980829
Drug: Chlorhexidine -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine - Chitosan combination
Trial: 33440437
Drug: EUS-guided intratumoral
RxNorm normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EUS-guided intratumoral radioactive phosphorus-32 (32P) implantation followed by six chemotherapy cycles
Trial: 32732620
Drug: High vagal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High vagal efficiency treatment group
Trial: 32880803
Drug: Low-dose rivaroxaban
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rivaroxaban
Trial: 36100927
Drug: HBOT (Hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOT (Hyperbaric Oxygen Treatment)
Trial: 32564365
Drug: Lidocaine (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (bolus of 1.5 mg.kg−1, continuous infusion of 2 mg.kg−1.h−1 until end of surgery, then 1 mg.kg−1.h−1 for 1 hour in recovery)
Trial: 34060209
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide (initial 3 mg dose)
Trial: 32940243
Drug: Treatment attributes
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment attributes (effectiveness and out-of-pocket cost)
Trial: 32544350
Drug: Treatment (post-surgery)
RxNorm normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (post-surgery)
Trial: 35881121
Drug: Low-dose tranexamic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tranexamic acid
Trial: 34753425
Drug: TMQLB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMQLB with 0.4 ml/kg 0.5% ropivacaine
Trial: 33081606
Drug: Vilanterol (VI)
RxNorm normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vilanterol (VI) 25 µg
Trial: 35508923
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g beetroot (272 mg NO3‐)
Trial: 35508923
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g beetroot (544 mg NO3‐)
Trial: 35508923
Drug: 300 g
RxNorm normalized name: Zantac 300 GELdose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g beetroot (816 mg NO3‐)
Trial: 35508923
Drug: 200-ml solution
RxNorm normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-ml solution containing 1000 mg potassium nitrate (KNO3)
Trial: 34404091
Drug: Local vibration
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local vibration therapy (VT)
Trial: 32493288
Drug: Cisplatin low
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin low cumulative dose (≤150 mg/m2)
Trial: 32493288
Drug: Cisplatin intermediate
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin intermediate cumulative dose (151-250 mg/m2)
Trial: 32493288
Drug: Cisplatin high
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin high cumulative dose (>250 mg/m2)
Trial: 32493288
Drug: Overall population
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall population (all cumulative doses)
Trial: 35103059
Drug: Bromhexine hydrochloride
RxNorm normalized name: bromhexine hydrochloride
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine hydrochloride (8 mg 3 times per day)
Trial: 32104959
Drug: Palatal augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palatal augmentation prostheses (PAP)
Trial: 35554758
Drug: Immuno-sympathoinhibitory EA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immuno-sympathoinhibitory EA treatment
Trial: 35554758
Drug: Sympathoinhibitory EA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sympathoinhibitory EA treatment
Trial: 32595918
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g soy flour (whole soy group)
Trial: 32595918
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g low-fat milk powder + 63 mg daidzein (daidzein group)
Trial: 33118636
Drug: Edoxaban (low-dose:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (low-dose: 15 and 30 mg)
Trial: 32887548
Drug: Fremanezumab (quarterly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fremanezumab (quarterly or monthly)
Trial: 38761811
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment alone
Trial: 34118115
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg DPV ring
Trial: 34118115
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg DPV ring
Trial: 34118115
Drug: Monthly 25
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly 25 mg DPV ring
Trial: 34344273
Drug: Standardized educational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized educational intervention on cancer pain management and analgesics (10-15 minutes)
Trial: 35395427
Drug: Curative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curative treatment (n = 78)
Trial: 35395427
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (17 patients)
Trial: 35395427
Drug: RCT comparing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT comparing endovascular with surgical treatment (20 patients)
Trial: 33181169
Drug: Transcutaneous application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous application of gaseous CO2 (CO2 therapy) for 4 weeks
Trial: 33181169
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with transcutaneous application of air for 4 weeks
Trial: 35057599
Drug: Tofacitinib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (10 mg for 14 days)
Trial: 35057599
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SOC) treatment alone
Trial: 32134320
Drug: weekly written
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: weekly written feedback individualized by a counselor
Trial: 35486012
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (eye acupuncture + exercise therapy)
Trial: 33561963
Drug: Monthly high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly high-dose vitamin D supplementation (initial dose of 200,000 IU vitamin D3 followed by 100,000 IU monthly)
Trial: 38743288
Drug: Monthly high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly high-dose vitamin D supplementation
Trial: 32151236
Drug: Robotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic therapy (ReoGeo system) plus standard therapy
Trial: 32151236
Drug: Self-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-guided therapy plus standard therapy
Trial: 35074433
Drug: DWI-guided dose-painting
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWI-guided dose-painting intensity modulated radiation therapy (DP-IMRT)
Trial: 34292204
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of oral naltrexone (n = 42)
Trial: 33098212
Drug: Standard pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pump therapy with CGM initiation delayed for 6 months
Trial: 39714936
Drug: Hybrid closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid closed-loop insulin delivery
Trial: 33275819
Drug: Selegiline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline and symptomatic treatment for iRBD
Trial: 35150818
Drug: Barberry group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barberry group (10 g/day dried purple-black barberry powder, once daily for 2 months)
Trial: 32969197
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention (LS) with cognitive behavioral therapy, nutrition advice, and exercise
Trial: 32969197
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention (LS) with cognitive behavioral therapy, nutrition advice, exercise, and SMS
Trial: 35780511
Drug: Treatment completers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment completers
Trial: 38682335
Drug: No lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lipid-lowering therapy
Trial: 33962565
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose 0.6 µg/kg in 10 min before anaesthesia induction, followed by continuous infusion 0.5 µg/kg/hr until 1 hour before end of surgery)
Trial: 32558989
Drug: Danicamtiv (50–100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danicamtiv (50–100 mg twice daily for 7 days)
Trial: 35578822
Drug: Stabilized hypochlorous
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilized hypochlorous acid solution
Trial: 35578822
Drug: Control (sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (sterile 0.9% NaCl) solution
Trial: 35034017
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CCRT) with adjuvant chemotherapy (AC)
Trial: 35034017
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CCRT) without adjuvant chemotherapy (AC)
Trial: 33942566
Drug: PN-943, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PN-943, 100 to 1400 mg (single doses)
Trial: 33942566
Drug: PN-943, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PN-943, 100 to 1000 mg (multiple doses)
Trial: 33942566
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg PN-943 (twice daily)
Trial: 33942566
Drug: PN-943 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PN-943 (multiple doses)
Trial: 33942566
Drug: PN-943 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PN-943 (single and multiple doses)
Trial: 32044319
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg upadacitinib twice daily
Trial: 32044319
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg upadacitinib twice daily
Trial: 32044319
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg upadacitinib twice daily
Trial: 32044319
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg upadacitinib twice daily
Trial: 32044319
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg upadacitinib once daily
Trial: 36934327
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (CONV)
Trial: 32687741
Drug: Prasugrel (reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (reduced dose in elderly or low-weight group)
Trial: 32687741
Drug: Ticagrelor (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (standard dose)
Trial: 32687741
Drug: Prasugrel (reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (reduced dose in neither elderly nor low-weight group)
Trial: 34413118
Drug: Insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin icodec
Trial: 35710576
Drug: bDMARD tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bDMARD tapering according to a strategy that combines disease activity guided dose optimization (DGDO) with a dynamic flare prediction model.
Trial: 35710576
Drug: disease activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: disease activity guided dose optimization (DGDO)
Trial: 35710576
Drug: bDMARD tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bDMARD tapering according to a strategy that combines DGDO with the dynamic flare prediction model.
Trial: 33648940
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E (780 mg EGCG daily for 6 months)
Trial: 32677772
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (diphereline) at two doses, 8 weeks before endometrial preparation
Trial: 32677772
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with estradiol valerate (6-8 mg/day)
Trial: 32677772
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (diphereline)
Trial: 33309349
Drug: Flunixin meglumine
RxNorm normalized name: Flunixin Meglumine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunixin meglumine (FLU) 2.2 mg/kg i.v. and whey protein placebo orally
Trial: 33309349
Drug: Meloxicam (MEL)
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam (MEL) 1 mg/kg orally and 2 mL/45 kg sterile saline placebo i.v.
Trial: 34911681
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg intravenously on days 1 and 15 + Tadalafil 10 mg orally once daily for 4 weeks
Trial: 33344227
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg intravenously on days 1 and 15
Trial: 34669179
Drug: Sonidegib 200
RxNorm normalized name: sonidegib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonidegib 200 mg once daily
Trial: 33347567
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation of 10 μg daily from age 2 weeks to 2 years
Trial: 33347567
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation of 30 μg daily from age 2 weeks to 2 years
Trial: 33347567
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of group 30 (30 μg) vs group 10 (10 μg)
Trial: 33347567
Drug: Highest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quartile of 25(OH)D (> 121 nmol/L)
Trial: 36138362
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with immunotherapy
Trial: 35322373
Drug: G-CSF plus
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF plus standard medical therapy
Trial: 35322373
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus standard medical therapy
Trial: 35122371
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis (IVT) alone
Trial: 32474650
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 μg subcutaneous daily)
Trial: 32474650
Drug: Risedronate (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (35 mg oral weekly)
Trial: 33739197
Drug: Control (medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (medical therapy alone)
Trial: 33091344
Drug: Flexible assertive
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible assertive community treatment (FACT)
Trial: 35732397
Drug: mHealth application
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth application for treatment support
Trial: 32623928
Drug: Bleomycin‐containing combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin‐containing combination chemotherapy regimen
Trial: 33188552
Drug: Bergamot phytosome
RxNorm normalized name: BERGAMOT
DrugBank: Bergamot oil (DB14335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bergamot phytosome (500 mg, two daily tablets)
Trial: 33188552
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two daily tablets)
Trial: 36195936
Drug: Radiofrequency microtenotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency microtenotomy treatment, patient education, and a heel insert
Trial: 33940563
Drug: Agomelatine in
RxNorm normalized name: Product containing agomelatine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine in combination with conventional cerebrovascular disease medication
Trial: 33940563
Drug: Sertraline in
RxNorm normalized name: Product containing sertraline in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline in combination with conventional cerebrovascular disease medication
Trial: 33940563
Drug: Escitalopram in
RxNorm normalized name: Product containing escitalopram in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram in combination with conventional cerebrovascular disease medication
Trial: 33940563
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone (Control group)
Trial: 39587796
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg)
Trial: 36235553
Drug: Insulin levels
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin levels at 4 months
Trial: 39374130
Drug: Individualized Assessment
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized Assessment and Treatment Program (IATP)
Trial: 34014689
Drug: Conventional motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional motivational enhancement + cognitive-behavioral treatment (MET-CBT)
Trial: 32341121
Drug: Tolcapone (COMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone (COMT inhibitor)
Trial: 32862453
Drug: Micronutrient powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient powder containing 12 mg iron for 12 weeks
Trial: 33581820
Drug: tE2 patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tE2 patches (four 100 μg patches per 24 h, changed twice weekly)
Trial: 33581820
Drug: tE2 patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tE2 patches
Trial: 32182364
Drug: Follow-up after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up after treatment
Trial: 33928797
Drug: GP40071 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP40071 insulin aspart (GP‐Asp)
Trial: 35413921
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus icatibant (30 mg subcutaneously 3 times a day for 3 days)
Trial: 32638445
Drug: Cinnamon powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon powder (three capsules/day each containing 600 mg of cinnamon)
Trial: 32638445
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three capsules/day each containing 100 mg of corn starch)
Trial: 33906807
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL PRP intracavernosal injections, n = 30
Trial: 33906807
Drug: Placebo intracavernosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intracavernosal injections, n = 30
Trial: 32601289
Drug: Mustard aphid
RxNorm normalized name: MUSTARD
DrugBank: White mustard seed (DB15606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mustard aphid (L. erysimi)
Trial: 33894153
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 600,000 IU of vitamin D3
Trial: 32883721
Drug: Internet-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based intervention based on Acceptance and Commitment Therapy (ACT), 7 modules over 7 weeks, guided by a trained e-coach.